• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Fever"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 30

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study 

      Kalofonos, H. P.; Kardamakis, D.; Bamias, A. T.; Skarlos, Dimosthenis V.; Papakostas, P.; Bafaloukos, Dimitrios; Sakantamis, A.; Pavlidis, Nicholas; Fountzilas, George (2003)
      Background: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied ...

    • Article  

      Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study 

      Briassoulis, E. Ch; Pentheroudakis, George; Timotheadou, H.; Rammou, D.; Pavlidis, Nicholas; Fountzilas, George (2004)
      We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...

    • Article  

      Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG) 

      Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)
      Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...

    • Article  

      Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features 

      Pentheroudakis, George; Kostadima, Lida; Fountzilas, George; Kalogera-Fountzila, Anna; Klouvas, G. D.; Kalofonos, H. P.; Pavlidis, Nicholas (2004)
      Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...

    • Article  

      CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group 

      Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)
      Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

    • Article  

      Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group 

      Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)
      To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...

    • Article  

      Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) 

      Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)
      In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

    • Article  

      Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study 

      Sternberg, Cora N.; Huinink, W. W. Ten Bokkel; Smyth, J. F.; Bruntsch, V.; Dirix, L. Y.; Pavlidis, Nicholas; Franklin, H. R.; Wanders, S.; Bail, N. Le; Kaye, Stanley B. (1994)
      Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were ...

    • Article  

      Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer. A randomized phase III study conducted by the Hellenic Cooperative Oncology Group 

      Fountzilas, George; Zisiadis, A.; Dafni, U.; Konstantaras, C.; Hatzitheoharis, G.; Papavramidis, S.; Bousoulegas, A.; Basdanis, G.; Giannoulis, E.; Dokmetzioglou, J.; Katsohis, C.; Nenopoulou, E.; Karvounis, N.; Briassoulis, E. Ch; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2000)
      Background: It has been shown in randomized studies that adjuvant treatment with the combination of fluorouracil (FU) and levamisole reduced the risk of recurrence and deaths of patients with stage III colon cancer. ...

    • Article  

      Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study 

      Skarlos, Dimosthenis V.; Kalofonos, H. P.; Fountzilas, George; Dimopoulos, M. A.; Pavlidis, Nicholas; Razi, E. D.; Economopoulos, T.; Pectasides, Dimitrios; Gogas, H.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Klouvas, G. D.; Kyratzis, G.; Aravantinos, Gerasimos (2005)
      Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory ...

    • Article  

      Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation 

      Mauri, D.; Pentheroudakis, George; Ch, F. Tolis; Chojnacka, M.; Pavlidis, Nicholas (2005)
      Purpose: To identify the incidence of prostate cancer associated-systemic inflammatory syndrome (SIS), and to characterize further this entity, we searched our database as well as the medical literature. Methods: We ...

    • Article  

      Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer 

      Fountzilas, George; Skarlos, Dimosthenis V.; Giannakakis, T.; Athanasiades, A.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Bamia, C.; Pavlidis, Nicholas; Kosmidis, Paraskevas A. (1994)
      50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...

    • Article  

      Late toxicity in survivors from adolescent cancers 

      Pentheroudakis, George; Pavlidis, Nicholas (2007)
      Nowadays three quarters of adolescents with cancer are cured but half of them experience a late toxic effect of antineoplastic therapy that interferes with their physical and psychosocial health. This review recapitulates ...

    • Article  

      Management of leptomeningeal malignancy 

      Pentheroudakis, George; Pavlidis, Nicholas (2005)
      Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane. Leukaemias and lymphomas, lung, breast cancer and melanoma are the primary tumours commonly associated with ...

    • Article  

      Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study 

      Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)
      Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...

    • Article  

      Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study 

      Aravantinos, Gerasimos; Fountzilas, George; Kosmidis, Paraskevas A.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, Dimosthenis V. (2005)
      Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin ...

    • Article  

      Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors 

      Pentheroudakis, George; Fountzilas, George; Kalofonos, H. P.; Golfinopoulos, Vassilis; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Papakostas, P.; Pectasides, Dimitrios; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, Nicholas (2008)
      Introduction: Cancer in the elderly is a common health issue in developed societies. We sought to present epidemiology, management and outcome data on fit elderly patients with common metastatic cancers and to identify ...

    • Article  

      Phase II Study of 5-Fluorouracil and Interferon-Gamma in Patients with Metastatic Colorectal Cancer 

      Pavlidis, Nicholas; Nikolaides, C.; Athanasiades, A.; Beriatou, K.; Skarlos, Dimosthenis V.; Giannakakis, T.; Kosmidis, Paraskevas A.; Karvounis, N.; Fountzilas, George (1996)
      Preclinical data have shown a synergism between 5-fluorouracil and interferon-γ against human colon carcinoma cell lines. We conducted a phase II trial of this combination in 34 patients with metastatic colorectal cancer. ...

    • Article  

      Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer 

      Kerbrat, P.; Dieras, V.; Pavlidis, Nicholas; Ravaud, A.; Wanders, J.; Fumoleau, P. (2003)
      LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had ...

    • Article  

      A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: A Hellenic Cooperative Oncology Group (HeCOG) study 

      Kalofonos, H. P.; Nikolaides, C.; Samantas, E.; Mylonakis, N.; Aravantinos, Gerasimos; Dimopoulos, M. A.; Gennatas, Constantinos; Kouvatseas, G.; Giannoulis, E.; Dervenis, C.; Basdanis, G.; Pavlidis, Nicholas; Androulakis, G.; Fountzilas, George (2002)
      We conducted a phase III study in patients with advanced colorectal carcinoma (ACC). The total number of patients randomized from October 1993 until July 1998 was 192, whereas therapy was started on 179 and 158 (82.3%) ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD